Castle Biosciences, Inc. - CSTL STOCK NEWS

Castle Biosciences (Nasdaq: CSTL) reported findings from a study on uveal melanoma patients' attitudes towards prognostic testing with DecisionDx-UM. The research, presented at the 20th International Society of Ocular Oncology congress, showed that 90% of 177 surveyed patients desired prognostic information at diagnosis. Notably, there was no significant difference in decision regret among varying risk classifications (Class 1A, 1B, Class 2). Patients appreciated the insights gained from the test, including better understanding of their disease and personalized treatment options.

Castle Biosciences (CSTL) announced new findings demonstrating that its tests, DecisionDx-Melanoma and DecisionDx-SCC, can significantly improve patient management in skin cancer treatment. A pooled analysis revealed that DecisionDx-Melanoma effectively identifies high-risk melanoma patients among traditionally low-risk groups, with a notable difference in 3-year recurrence-free survival rates (75.9% vs. 97.7%). Additionally, a survey of dermatologic clinicians indicated that DecisionDx-SCC results can lead to risk-aligned treatment adjustments. The lab workflow for MyPath Melanoma and DecisionDx DiffDx-Melanoma achieved over 99% reporting of actionable results.

Castle Biosciences (CSTL) has partnered with Oregon Health & Science University in the War on Melanoma, a public health initiative aimed at early detection and prevention of melanoma. This collaboration supports education and awareness programs, including the Start Seeing Melanoma campaign and the Skin Crew, which involves professionals identifying potential skin cancer signs. Castle emphasizes the importance of early diagnosis in improving patient outcomes. The company continues to focus on innovative tests to enhance patient care and disease management.

Castle Biosciences announced the results of a recent poster presentation regarding its DecisionDx®-Melanoma test at the 2022 Fall Clinical Dermatology Conference. The study surveyed 120 melanoma patients and revealed that 90% wanted prognostic information at diagnosis. The findings indicate that patients value the insights provided by the DecisionDx-Melanoma test, with over 90% finding it useful for understanding their condition. The test has been ordered 97,288 times, suggesting its growing adoption in clinical settings.

Castle Biosciences (Nasdaq: CSTL) announces a presentation at the JMP Securities Life Sciences Conference on June 16, 2022, by CEO Derek Maetzold and CFO Frank Stokes at 10:30 a.m. Eastern time. A live audio webcast will be accessible on Castle's website, with a replay available for two weeks post-event. The company focuses on innovative diagnostic tests for various cancers and health conditions, aiming to enhance patient care through advanced solutions. For details, visit CastleBiosciences.com.

Castle Biosciences has been awarded the 'Best New Technology Solution – Dermatology' in the MedTech Breakthrough Awards for its DecisionDx®-Melanoma gene expression profile test. This award recognizes Castle's innovation in predicting the risk of metastasis and recurrence in patients with invasive cutaneous melanoma. The DecisionDx-Melanoma test combines clinical factors with tumor biology, providing personalized treatment insights. In 2021, Castle's tests also received accolades in oncology, showcasing its commitment to improving patient care through advanced diagnostics.

Castle Biosciences (NASDAQ: CSTL) announced new study findings showing that its TissueCypher® Barrett’s Esophagus test can accurately predict progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus (BE). The study involved 154 patients and found that TissueCypher surpassed standard pathology, accurately identifying 71% of those who progressed, compared to 63% by pathologists. The test may help standardize care plans and improve management decisions for BE patients, reducing risks of missed diagnoses.

Castle Biosciences has partnered with Research to Prevent Blindness to enhance research opportunities for medical students focused on ocular cancer. The initiative includes funding for a fellowship that allows students to dedicate a year to ocular cancer research, addressing conditions like uveal melanoma, which affects approximately 2,000 individuals annually in the U.S. The fellowship offers a $30,000 grant, facilitating significant research contributions in this underrepresented field.